IP Library Granted Patent US 7,358,364
Granted Patent B2
US 7,358,364 · App. 10/823,842 · Granted Apr 15, 2008

Substituted carboxylic acids

Assignee: The Institute for Pharmaceutical Discovery LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,358,364
App. No.
10/823,842
Granted
Apr 15, 2008
Kind
B2
Abstract

The present invention relates to compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosine phosphatase (PTP-1B) that are useful in the treatment of diabetes and other PTP-1B mediated diseases, such as cancer, neurodegenerative diseases and the like. The compounds of the invention are also useful in pharmaceutical compositions and methods of treating the aforementioned conditions.

Claims (78)

1. A compound of the formula:

or a pharmaceutically acceptable salt thereof, wherein

n is 0, 1, 2, 3, or 4;

R 1 is H, C 1 -C 6 alkyl, phenyl(C 1 -C 6 )alkyl, or C 3 -C 6 alkenyl;

R 2 is phenyl, phenyl(C 1 -C 4 ) alkyl, C 1 -C 6 alkyl, —(C 1 -C 4 ) alkyl-C(O)NH 2 , —(C 1 -C 4 ) alkyl-C(O)NH(C 1 -C 4 )alkyl, —(C 1 -C 4 ) alkyl-C(O)N(C 1 -C 4 )alkyl(C 1 -C 4 )alkyl, —(C 1 -C 4 ) alkyl-S(O) b —(C 1 -C 4 ) alkyl, (C 1 -C 4 ) hydroxyalkyl, —(C 1 -C 4 ) alkyl-phthalimidyl, —(C 1 -C 4 ) alkyl-piperidinyl, —(C 1 -C 4 ) alkyl-pyrrolidinyl, —(C 1 -C 4 ) alkyl-morpholinyl, wherein the phthalimidyl, piperidinyl, pyrrolidinyl, or morpholinyl groups are optionally fused to a phenyl ring and wherein said phthalimidyl, piperidinyl, pyrrolidinyl, or morpholinyl groups are, the phenyl portion, or both are optionally substituted with a total of 1, 2, 3, or 4 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —SO 2 —(C 1 -C 4 ) alkyl (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy;

wherein b is 0, 1, or 2;

R 20 , R 21 , R 22 , and R 23 are independently H, arylalkoxy, arylalkyl, halogen, alkyl, haloalkyl, OH, alkoxy, NO 2 , NH 2 , NH(C 1 -C 6 )alkyl, N(C 1 -C 6 alkyl)(C 1 -C 6 alkyl), NH-aryl, NHC(O)—(C 1 -C 4 alkyl)-aryl, N(C 1 -C 4 alkyl)C(O)—(C 1 -C 4 )alkyl-aryl, N(C 1 -C 4 ) alkyl-aryl, —NHSO 2 -aryl, or —N(C 1 -C 4 alkyl) SO 2 aryl, wherein each of the above aryl groups are optionally substituted with 1, 2, 3, or 4 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, OH, NO 2 , haloalkyl, haloalkoxy;

L is O;

L 3 is a bond, —(C 1 -C 4 )alkyl-O—, —O-(C 1 -C 4 )alkyl, —(C 1 -C 4 ) alkyl-, —C(O)—, —C(O)NH—, or —NHC(O)—;

the A-ring is aryl selected from the group consisting of phenyl, naphthyl and fluorenyl, each of which is optionally substituted with 1, 2, or 3 groups that are independently, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, NO 2 , NH 2 , NH(C 1 -C 6 )alkyl, N(C 1 -C 6 )alkyl(C 1 -C 6 )alkyl;

Q is pyrido [1,2-a]indolyl, indolyl, isoindolyl, indolizinyl, imidazo[1,2-a]pyridine, -phenyl-C(O)-phenyl, -phenyl-(C 1 -C 4 ) alkyl-phenyl, -pyridyl-phenyl, fluorenyl, oxofluorenyl, -fluorenyl-pyridyl, -fluorenyl-phenyl, -benzimidazolyl-(C 1 -C 4 ) alkyl-phenyl, benzoxazolyl-(C 1 -C 4 ) alkyl-phenyl, indolizinyl, -indolyl-(C 1 -C 4 )alkyl-phenyl, -phenyl-benzoxazolyl, dibenzo[b,d]furanyl, or dibenzothienyl, each of which is optionally substituted with 1, 2, 3, or 4 groups that are independently C 1 -C 6 alkyl, C 1 -C 4 alkoxycarbonyl, C 1 -C 6 alkoxy, halogen, haloalkyl, haloalkoxy, NR 6 R 7 , or phenyl; wherein

R 6 and R 7 are independently H, C 1 -C 6 alkyl, aryl(C 1 -C 6 )alkyl, alkanoyl, phenyl(C 1 -C 4 )alkanoyl, alkoxycarbonyl, phenyl(C 1 -C 4 )alkoxycarbonyl, pyridylcarbonyl, pyridyl, piperidinyl, pyrrolidinylcarbonyl, —C(O)NH 2 , —C(O)NH(C 1 -C 6 )alkyl, —C(O)N(C 1 -C 6 )alkyl (C 1 -C 6 )alkyl, or —SO 2 -phenyl, wherein the cyclic groups are optionally substituted with 1, 2, 3, or 4 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, NO 2 , OH, NH 2 , NH(C 1 -C 6 )alkyl, N(C 1 -C 6 )alkyl(C 1 -C 6 )alkyl, CF 3 or OCF 3 .

2. A compound according to claim 1 , wherein

the A-ring is selected from phenyl, or naphthyl, each of which is optionally substituted with 1, 2, or 3 groups that are independently, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, NO 2 , NH 2 , NH(C 1 -C 6 )alkyl, or N(C 1 -C 6 )alkyl (C 1 -C 6 )alkyl; and

R 20 , R 21 , R 22 , and R 23 are independently H, phenylalkoxy, phenylalkyl, halogen, alkyl, CF 3 , OH, alkoxy, NO 2 , NH 2 , NH(C 1 -C 6 )alkyl, N(C 1 -C 6 )alkyl(C 1 -C 6 )alkyl, NH-phenyl, NHC(O)—(C 1 -C 4 ) alkyl-phenyl, N(C 1 -C 4 alkyl)C(O)-(C 1 -C 4 ) alkyl-phenyl, N(C 1 -C 4 )alkyl-phenyl, —NHSO 2 -phenyl, or —N(C 1 -C 4 alkyl)SO 2 phenyl, wherein the phenyl groups are optionally substituted with 1, 2, 3, or 4 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, OH, NO 2 , C 1 -C 2 haloalkyl, or C 1 -C 2 haloalkoxy.

3. A compound according to claim 2 , of the formula

wherein

R 1 is H or C 1 -C 6 alkyl;

R 2 is phenyl, phenyl(C 1 -C 4 ) alkyl, C 1 -C 6 alkyl, —(C 1 -C 4 ) alkyl-C(O)NH 2 , —(C 1 -C 4 ) alkyl-S(O) b -(C 1 -C 4 ) alkyl, or (C 1 -C 4 ) hydroxyalkyl, wherein the phenyl groups are optionally substituted with 1, 2, 3, or 4 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —SO 2 —(C 1 -C 4 ) alkyl, (C 1 -C 4 )haloalkyl, or (C 1 C 4 )haloalkoxy;

v is 0, 1, 2, 3, or 4;

R 10 at each occurrence is independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, NO 2 , NH 2 , NH(C 1 -C 6 )alkyl, or N(C 1 -C 6 )alkyl(C 1 -C 6 )alkyl; and

L 3 is a bond, —O—(C 1 -C 4 )alkyl, —(C 1 -C 4 ) alkyl-, or —C(O)—.

4. A compound according to claim 3 , wherein

Q is pyrido[1,2-a]indolyl, indolyl, imidazo[1,2-a]pyridine, -phenyl-C(O)-phenyl, -phenyl-(C 1 -C 4 ) alkyl-phenyl, fluorenyl, indolizinyl, -indolyl-(C 1 -C 4 )alkyl-phenyl, -phenyl-benzoxazolyl, dibenzo[b,d]furanyl, or dibenzothienyl, each of which is optionally substituted with 1, 2, 3, or 4 groups that are independently C 1 -C 6 alkyl, C 1 -C 4 alkoxycarbonyl, C 1 -C 6 alkoxy, halogen, haloalkyl, haloalkoxy, NR 6 R 7 , or phenyl; wherein

R 6 and R 7 are independently H, C 1 -C 6 alkyl, aryl(C 1 -C 6 )alkyl, alkanoyl, phenyl(C 1 -C 4 )alkanoyl, alkoxycarbonyl, phenyl(C 1 -C 4 )alkoxycarbonyl, pyridylcarbonyl, pyridyl, pyrrolidinylcarbonyl, or —SO 2 -phenyl, wherein the cyclic groups are optionally substituted with 1, 2, 3, or 4 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, NO 2 , OH, NH 2 , NH(C 1 -C 6 )alkyl, N(C 1 -C 6 )alkyl (C 1 -C 6 )alkyl, CF 3 or OCF 3 .

5. A compound according to claim 4 , wherein

R 2 is phenyl, phenyl(C 1 -C 4 ) alkyl, or (C 1 -C 6 )alkyl, wherein the phenyl groups are optionally substituted with 1, 2, 3, or 4 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or —SO 2 —(C 1 -C 4 ) alkyl, CF 3 or OCF 3 ; and

R 20 , R 21 , R 22 , and R 23 are independently selected from H, halogen, alkyl, OH, alkoxy, NO 2 , NH 2 , NH(C 1 -C 6 )alkyl, or N(C 1 -C 6 alkyl)(C 1 -C 6 alkyl).

6. A compound according to claim 5 , wherein

L 3 is a bond, —O—(C 1 -C 4 )alkyl, —(C 1 -C 4 ) alkyl-, or —C(O)—;

Q is indolyl, -phenyl-C(O)-phenyl, indolizinyl, -indolyl-(C 1 -C 4 )alkyl-phenyl, dibenzo[b,d]furanyl, or dibenzothienyl, each of which is optionally substituted with 1, 2, 3, or 4 groups that are independently C 1 -C 6 alkyl, C 1 -C 4 alkoxycarbonyl, C 1 -C 6 alkoxy, halogen, haloalkyl, haloalkoxy, NR 6 R 7 , or phenyl; wherein

R 6 and R 7 are independently H, C 1 -C 6 alkyl, phenyl(C 1 -C 6 )alkyl, alkanoyl, phenyl(C 1 -C 4 )alkanoyl, alkoxycarbonyl, pyridylcarbonyl, pyridyl, pyrrolidinylcarbonyl, or —SO 2 -phenyl, wherein the cyclic groups are optionally substituted with 1, 2, 3, or 4 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, NO 2 , OH, NH 2 , NH(C 1 -C 6 )alkyl, N(C 1 -C 6 )alkyl(C 1 -C 6 )alkyl, CF 3 or OCF 3 .

7. A compound according to claim 6 of the formula:

8. A compound according to claim 7 , wherein

R 1 is H;

R 21 is H, NO 2 , C 1 -C 6 alkyl, or halogen; and

R 2 is phenyl, phenyl(C 1 -C 4 )alkyl, or (C 1 -C 6 )alkyl, wherein each phenyl group is optionally substituted with 1, 2, 3, or 4 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or —SO 2 —(C 1 -C 4 ) alkyl, CF 3 or OCF 3 .

9. A compound according to claim 8 , wherein

L 3 is a bond, —O—(C 1 -C 4 )alkyl, or —(C 1 -C 4 ) alkyl-;

Q is indolyl, -phenyl-C(O)-phenyl, indolizinyl, or -indolyl-(C 1 -C 4 )alkyl-phenyl, each of which is optionally substituted with 1, 2, 3, or 4 groups that are independently C 1 -C 6 alkyl, C 1 -C 4 alkoxycarbonyl, C 1 -C 6 alkoxy, halogen, haloalkyl, haloalkoxy, NR 6 R 7 , or phenyl; wherein

R 6 and R 7 are independently H, C 1 -C 6 alkyl, phenyl(C 1 -C 6 )alkyl, alkanoyl, phenyl(C 1 -C 4 )alkanoyl, alkoxycarbonyl, pyridylcarbonyl, pyrrolidinylcarbonyl, or —SO 2 -phenyl, wherein the cyclic groups are optionally substituted with 1, 2, 3, or 4 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, NO 2 , OH, NH 2 , NH(C 1 -C 6 )alkyl, N(C 1 -C 6 )alkyl (C 1 -C 6 )alkyl, CF 3 or OCF 3 .

10. A compound according to claim 1 selected from the group consisting of

({4′-[3-(benzylamino)imidazo[1,2-a]pyridin-2-yl]biphenyl-4-yl}oxy)(phenyl)acetic acid;

{[4′-(5-methyl-1H-indol-1-yl)biphenyl-4-yl]oxy}(phenyl)acetic acid;

({4′-[3-(butylamino)imidazo[1,2-a]pyridin-2-yl]biphenyl-4-yl}oxy)(phenyl)acetic acid;

methyl ({4-[(2-benzoylphenoxy)methyl]biphenyl-4-yl}oxy)(phenyl)acetate;

methyl ({4′-[(2-benzylphenoxy)methyl]biphenyl-4-yl}oxy)(phenyl)acetate;

methyl ({4′-[(9H-fluoren-2-yloxy)methyl]biphenyl-4-yl}oxy)(phenyl)acetate;

methyl ({4′-[(3-benzoylphenoxy)methyl]biphenyl-4-yl}oxy)(phenyl)acetate;

({4′-[(3-benzoylphenoxy)methyl]biphenyl-4-yl}oxy)(phenyl)acetic acid;

({4′-[(2-benzoylphenoxy)methyl]biphenyl-4-yl}oxy)(phenyl)acetic acid;

{[4′-(1-butylindolizin-2-yl)biphenyl-4-yl]oxy}(phenyl)acetic acid;

({4′-[10-(ethoxycarbonyl)pyrido[1,2-a]indol-3-yl]biphenyl-4-yl}oxy)(phenyl)acetic acid;

{[4′-(1H-indol-1-yl)biphenyl-4-yl]oxy}(phenyl)acetic acid;

methyl {[4′-(1-benzyl-1H-indol-6-yl)biphenyl-4-yl]oxy}(phenyl)acetate;

{[4′-(1-benzyl-1H-indol-6-yl)biphenyl-4-yl]oxy}(phenyl)acetic acid;

({[4′-(1-benzyl-1H-indol-5-yl)biphenyl-4-yl]oxy}(phenyl)acetic acid;

2-{[4′-(1-butylindolizin-2-yl)biphenyl-4-yl]oxy}propanoic acid;

(2R)-2-{[4-(1-butylindolizin-2-yl)biphenyl-4-yl]oxy}-3-phenylpropanoic acid;

(2S)-2-{[4-(1-butylindolizin-2-yl)biphenyl-4-yl]oxy}-4-phenylbutanoic acid;

{[2″-(1,3-benzoxazol-2-yl)-1,1′:4′,1″-terphenyl-4-yl]oxy}(phenyl)acetic acid;

[(4′-dibenzo[b,d]furan-4-ylbiphenyl-4-yl)oxy](phenyl)acetic acid;

[(4′-{[(9-oxo-9H-fluoren-1-yl)oxy]methyl}biphenyl-4-yl)oxy](phenyl) acetic acid;

methyl {[4′-(1-benzyl-1H-indol-5-yl)biphenyl-4-yl]oxy}(phenyl)acetate;

[(4′-dibenzo[b,d]thien-4-ylbiphenyl-4-yl)oxy](phenyl)acetic acid;

[4′-(5-Chloro-indol-1-yl)-biphenyl-4-yloxy]-phenyl-acetic acid;

(3-Chloro-4′-dibenzofuran-4-yl-biphenyl-4-yloxy)-phenyl-acetic acid;

(4′-Dibenzofuran-4-yl-2-methyl-biphenyl-4-yloxy)-phenyl-acetic acid;

(4′-Dibenzofuran-4-yl-3-fluoro-biphenyl-4-yloxy)-phenyl-acetic acid;

(2-Chloro-4′-dibenzofuran-4-yl-biphenyl-4-yloxy)-phenyl-acetic acid; and

(4′-Dibenzofuran-4-yl-2-trifluoromethyl-biphenyl-4-yloxy)-phenyl-acetic acid.

11. A compound selected from the group consisting of

{[4′-(1-benzofuran-2-yl)biphenyl-4-yl]oxy}(phenyl)acetic acid;

({4′-[(2-butyl-1-benzofuran-3-yl)carbonyl]biphenyl-4-yl}oxy)(phenyl)acetic acid;

{[4′-(1-benzothien-2-yl)biphenyl-4-yl]oxy}(phenyl)acetic acid;

[(4″-butyl-1,1′:4′,1″-terphenyl-4-yl)oxy](phenyl)acetic acid;

({4′-[(2-benzyl-7-fluoro-1-benzofuran-3-yl)carbonyl]biphenyl-4-yl}oxy)(phenyl)acetic acid; and

methyl {[4′-(1-benzofuran-2-yl)biphenyl-4-yl]oxy}(phenyl)acetate.

Assignments (3)
SECURITY RELEASE LETTER Recorded Sep 12, 2005
From: MPM BIOVENTURES III, L.P.; MPM BIOVENTURES III-QP, L.P.; MPM BIOVENTURES III GMBH & CO., BETEILIGUNGS KG; MPM BIOVENTURES III PARALLEL FUND, L.P.; MPM ASSET MANAGEMENT INVESTORS 2005, BVIII LLC.
To: INSTITUTES FOR PHARMACEUTICAL DISCOVERY, L.L.C.; INSTITUTE FOR DIABETES DISCOVERY, L.L.C.
Reel/Frame 016513/0792 →
SECURITY AGREEMENT Recorded Mar 3, 2005
From: INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC, THE; INSTITUTE FOR DIABETES DISCOVERY, LLC
To: MPM BIOVENTURES III, L.P.; MPM BIOVENTURES III-QP, L.P.; MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG; MPM BIOVENTURES III PARALLEL FUND, L.P.; MPM ASSET MANAGEMENT INVESTORS 2005 BVIII LLC
Reel/Frame 016323/0360 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2004
From: VAN ZANDT, MICHAEL C.; WHITEHOUSE, DARREN; COMBS, KERRY; HU, SHAOJING
To: INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC, THE
Reel/Frame 015724/0108 →
Continuity (2)
Provisional Application 6046705700 · Apr 30, 2003
Related Publication 20040266788A1 · Dec 30, 2004